Related references
Note: Only part of the references are listed.Effects of Hepatic Impairment on the Pharmacokinetics of Everolimus: A Single-Dose, Open-Label, Parallel-Group Study
Jan Peveling-Oberhag et al.
CLINICAL THERAPEUTICS (2013)
Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo
Terry O'Reilly et al.
ANTI-CANCER DRUGS (2011)
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.
Juan Valle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data
Chiaki Tanaka et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors
Anne O'Donnell et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer
D Ito et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: Implications for patient management and clinical trial design
M Markman et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Influence of hepatic impairment on everolimus pharmacokinetics: Implications for dose adjustment
JM Kovarik et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2001)
Share Paper
